Arcus Biosciences Q2 Earnings Call Highlights

Impact · against what's priced in

RCUS gains a significant valuation anchor with a $5B-$10B peak sales target for casdatifan and a catalyst-rich October data window. Collaborations with BMY, AVEO, and SMMT provide modest validation of the asset's potential in combination regimens.

RCUS+0.80

No priced-in read yet

In context

Establishing a $5 billion to $10 billion peak sales potential for casdatifan provides a concrete valuation target, while the upcoming October data readout for over 200 patients serves as a high-volatility catalyst.

Read from the article alone

• earnings
• biotech
• AVEO
• BMY
• RCUS
• SMMT
• cancer research
• clinical trials
• fda
• immunology
• oncology